MSVNX
Price
$7.49
Change
-$0.31 (-3.97%)
Updated
Dec 18 closing price
VSIAX
Price
$85.23
Change
-$3.35 (-3.78%)
Updated
Dec 18 closing price
Ad is loading...

MSVNX vs VSIAX

Header iconMSVNX vs VSIAX Comparison
Open Charts MSVNX vs VSIAXBanner chart's image
MassMutual Small Company Val R3
Price$7.49
Change-$0.31 (-3.97%)
VolumeN/A
CapitalizationN/A
Vanguard Small Cap Value Index Admiral
Price$85.23
Change-$3.35 (-3.78%)
VolumeN/A
CapitalizationN/A
MSVNX vs VSIAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
MSVNX vs. VSIAX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MSVNX is a Sell and VSIAX is a Hold.

FUNDAMENTALS
Fundamentals
VSIAX has more cash in the bank: 63B vs. MSVNX (128M). VSIAX pays higher dividends than MSVNX: VSIAX (2.01) vs MSVNX (0.36). MSVNX was incepted earlier than VSIAX: MSVNX (22 years) vs VSIAX (13 years). MSVNX is a more actively managed with annual turnover of: 44.00 vs. VSIAX (16.00). MSVNX has a lower initial minimum investment than VSIAX: MSVNX (0) vs VSIAX (3000). MSVNX (16.95) and VSIAX (16.23) have marching annual gain over last year. VSIAX return over 5 years is better than : 52.83 vs. MSVNX (0.19).
MSVNXVSIAXMSVNX / VSIAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence22 years13 years-
Gain YTD14.60415.03197%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets128M63B0%
Annual Yield % from dividends0.362.0118%
Returns for 1 year16.9516.23104%
Returns for 3 years-12.2720.67-59%
Returns for 5 years0.1952.830%
Returns for 10 years-38.68105.65-37%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ALTO1.470.04
+2.80%
Alto Ingredients
ADXN7.80-0.05
-0.64%
Addex Therapeutics Ltd
DCOM33.96-0.84
-2.41%
Dime Community Bancshares
CAVA123.37-3.42
-2.70%
CAVA Group
EWTX30.17-2.52
-7.71%
Edgewise Therapeutics